| Literature DB >> 16504076 |
Mohammad Ali Boroumand1, Leila Sam, Seyed Hesameddin Abbasi, Mojtaba Salarifar, Ebrahim Kassaian, Saeedeh Forghani.
Abstract
BACKGROUND: The risk of developing infection in diabetic patients is higher and urinary tract is the most common site for infection. Serious complications of urinary infection occur more commonly in diabetic patients. To study the prevalence and associates of asymptomatic bacteriuria (ASB) in women with type 2 diabetes mellitus in the Iranian population, this study was conducted.Entities:
Year: 2006 PMID: 16504076 PMCID: PMC1402268 DOI: 10.1186/1472-6874-6-4
Source DB: PubMed Journal: BMC Womens Health ISSN: 1472-6874 Impact factor: 2.809
Participant Characteristics
| No. | 202 |
| Mean age (Y) | 56 ± 6.1 |
| Duration of diabetes (Y) | 4.5 ± 1.2 |
| Duration of diabetes (Median) | 4.3 |
| Pyuria | 17% |
| Macroalbuminuria | 12.1% |
| Glucosuria | 22.8% |
| Bacteriuria | 10.9% |
| HbA1c>8% | 43.1% |
| BUN (mg/dl) | 39.9 ± 7.5 |
| Creatinine (mg/dl) | 0.7 ± 0.2 |
The isolated microorganisms from urine cultures.
| Microorganisms | No (%) |
| E. Coli | 13 (59.1%) |
| Streptococcus hemolyticus group B | 3(13.6%) |
| Staphylococcus coagulase negative | 3(13.6%) |
| Pseudomonas auroginosa | 2(9.1%) |
| E. Coli + Pseudomonas auroginosa | 1(4.6%) |
| 22(100%) |
Urine isolates from diabetic women and their antibiotic sensitivity pattern
| E. Coli (14) | Staphylococcus Coagulase Negative (3) | Streptococcus Hemolyticus Group B (3) | Pseudomonas Auroginosa (3) | |||||
| Amikacin | 8 | 6 | 3 | 0 | 2 | 1 | 1 | 2 |
| Gentamicin | 8 | 6 | 2 | 1 | 2 | 1 | 1 | 2 |
| Ciprofloxacin | 5 | 9 | 2 | 1 | 1 | 2 | 1 | 2 |
| Cephalotin | 1 | 13 | 1 | 2 | 2 | 1 | 2 | 1 |
| Ceftazidime | 5 | 9 | NT | NT | NT | NT | 1 | 2 |
| Ceftriaxone | 0 | 1 | NT | NT | NT | NT | 1 | 2 |
| Nitrofurantion | 11 | 3 | 2 | 1 | 1 | 2 | NT | NT |
| Nalidixic acid | 4 | 10 | NT | NT | NT | NT | NT | NT |
| Cotrimoxazole | 4 | 10 | 2 | 1 | 2 | 1 | NT | NT |
| Tobramycin | NT* | NT | NT | NT | NT | NT | 1 | 2 |
| Clindamycin | NT | NT | 2 | 1 | 2 | 1 | NT | NT |
| Erythromycin | NT | NT | 1 | 2 | 2 | 1 | NT | NT |
| Vancomycin | 1 | 0 | 2 | 1 | 2 | 1 | NT | NT |
| Ceftizoxime | NT | NT | NT | NT | NT | NT | 0 | 3 |
| Ampicillin | NT | NT | NT | NT | 3 | 0 | NT | NT |
* NT = Not Tested